1.Trial hypothesis: Can umbilical cord mesenchymal stem cells be combined with standard drugs like Liraglutide to observe better outcomes with T2D?

Study ID: NCT01954147 Diabetes Care Center of Nanjing Military Command, Fujian, China

2. Trial hypothesis: Safety and effectiveness of combining umbilical cord and placenta-derived mesenchymal stem cells with oral drugs used to treat T2D

Study ID: NCT01413035 Shandong University

3. Trial hypothesis: Using umbilical cord mesenchymal stem cell injections to avoid the T2D complications associated with diabetic foot

Study ID: NCT01216865 Qingdao University